UCB reports positive data from epilepsy drug trial

UCB has announced positive topline results from a phase III trial of brivaracetam, its new therapy for epilepsy patients with partial-onset seizures.

The newest investigational medicine from UCB's late-stage pipeline has been evaluated as an adjunctive treatment for adult focal epilepsy patients with partial-onset seizures that have not been fully controlled despite treatment with one or two concomitant antiepileptic drugs (AEDs).

It was revealed that brivaracetam was able to significantly reduce partial-onset seizure frequency and improved responder rates compared to placebo.

The clinical development programme for the drug has involved more than 3,000 people to date. Based on the positive findings, regulatory submissions in the US and EU are planned for early 2015.

Jean-Christophe Tellier, chief executive officer-elect of UCB, said: "We are proud to provide AED options for the epilepsy community today and remain committed to addressing the unmet needs of adult patients who continue to experience uncontrolled seizures."

Mr Tellier is scheduled to take over leadership of the company at the beginning of 2015 and is working with current chief executive Roch Doliveux throughout 2014 to ensure a smooth transition.